港股异动 | 金斯瑞生物科技(01548)现涨近4% 传奇生物西达基奥仑赛3期CARTITUDE-4研究显示临床改善显著

智通财经07-05

智通财经APP获悉，金斯瑞生物科技(01548)现涨近4%，截至发稿，涨3.62%，报9.17港元，成交额2828.32万港元。消息面上，传奇生物于7月2日宣布，其CARVYKTI（cilta-cel，西达基奥仑赛）的3期CARTITUDE-4研究在预定的第二次中期分析中获得积极结果。数据显示，与标准疗法相比，对于复发且来那度胺耐药的多发性骨髓瘤成人患者（既往接受过一至三线治疗），西达基奥仑赛在总...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2449286128?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-05 10:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2449286128","market":"us","top_or_hot":-1,"title":"港股异动 | 金斯瑞生物科技(01548)现涨近4% 传奇生物西达基奥仑赛3期CARTITUDE-4研究显示临床改善显著","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，金斯瑞生物科技(01548)现涨近4%，截至发稿，涨3.62%，报9.17港元，成交额2828.32万港元。消息面上，传奇生物于7月2日宣布，其CARVYKTI（cilta-cel，西达基奥仑赛）的3期CARTITUDE-4研究在预定的第二次中期分析中获得积极结果。数据显示，与标准疗法相比，对于复发且来那度胺耐药的多发性骨髓瘤成人患者（既往接受过一至三线治疗），西达基奥仑赛在总...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1145984.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 金斯瑞生物科技(01548)现涨近4% 传奇生物西达基奥仑赛3期CARTITUDE-4研究显示临床改善显著</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 金斯瑞生物科技(01548)现涨近4% 传奇生物西达基奥仑赛3期CARTITUDE-4研究显示临床改善显著\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-05 10:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1145984.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，金斯瑞生物科技(01548)现涨近4%，截至发稿，涨3.62%，报9.17港元，成交额2828.32万港元。消息面上，传奇生物于7月2日宣布，其CARVYKTI（cilta-cel，西达基奥仑赛）的3期CARTITUDE-4研究在预定的第二次中期分析中获得积极结果。数据显示，与标准疗法相比，对于复发且来那度胺耐药的多发性骨髓瘤成人患者（既往接受过一至三线治疗），西达基奥仑赛在总...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1145984.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1145984.html","article_id":"2449286128","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2449286128","pubTimestamp":1720146700,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，金斯瑞生物科技现涨近4%，截至发稿，涨3.62%，报9.17港元，成交额2828.32万港元。消息面上，传奇生物于7月2日宣布，其CARVYKTI的3期CARTITUDE-4研究在预定的第二次中期分析中获得积极结果。该安全性结果与西达基奥仑赛已知安全性一致，未识别新的安全信号。此外，金斯瑞生物科技发公告称，内容有关西达基奥仑赛开发里程碑事件达成，传奇获得由强生支付的总计3.8亿美元的里程碑付款。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","HSTECH":"恒生科技指数","01548":"金斯瑞生物科技","YANG":"三倍做空富时中国ETF-Direxion","BK4505":"高瓴资本持仓","07226":"XL二南方恒科","BK4588":"碎股","LEGN":"传奇生物","BK1576":"医药外包概念","HSCEI":"国企指数","BK4585":"ETF&股票定投概念","BK1141":"生命科学工具和服务","BK4139":"生物科技"},"translate_title":"Changes in Hong Kong stocks GenScript Biotechnology (01548) is now up nearly 4% Legend Biotech Cedar Keolensai Phase 3 CARTITUDE-4 study shows significant clinical improvement","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1,"07226":1,"HSCEI":1,"HSTECH":1,"LEGN":1,"YANG":1},"content_text":"智通财经APP获悉，金斯瑞生物科技(01548)现涨近4%，截至发稿，涨3.62%，报9.17港元，成交额2828.32万港元。消息面上，传奇生物于7月2日宣布，其CARVYKTI（cilta-cel，西达基奥仑赛）的3期CARTITUDE-4研究在预定的第二次中期分析中获得积极结果。数据显示，与标准疗法相比，对于复发且来那度胺耐药的多发性骨髓瘤成人患者（既往接受过一至三线治疗），西达基奥仑赛在总生存期上显示出显著统计学差异且具有临床意义的改善。该安全性结果与西达基奥仑赛已知安全性一致，未识别新的安全信号。此外，金斯瑞生物科技发公告称，内容有关西达基奥仑赛(cilta-cel)开发里程碑事件达成，传奇获得由强生支付的总计3.8亿美元的里程碑付款。除上述外，传奇已根据与杨森就西达基奥仑赛订立的合作协议另外获得3000万美元的里程碑付款。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2449286128"}